Canaccord Genuity Cuts Fractyl Health Price Target to $39 From $96
Canaccord Genuity lowered its Fractyl Health target to $39 from $96 while keeping a Buy rating, according to Dow Jones Newswires citing Benzinga data.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Canaccord Genuity lowered its price target on Fractyl Health shares to $39 from $96 and kept its Buy rating on the stock.
The change was reported by Dow Jones Newswires, which cited ratings data from Benzinga and timed the update at 15:40 GMT.
why it matters
A cut of nearly 60% in the target signals that the analyst has revised its valuation of the company, while still holding a positive view. Such moves usually matter mainly to investors in GUTS rather than to the broader market.
market impact
GUTS: lower target reduces the valuation benchmark for the shares, while the Buy rating holds
tags
instruments
sources
- Fractyl Health Price Target Cut to $39.00/Share From $96.00 by Canaccord Genuity — Dow Jones Newswires, 20 October 2026 at 15:40 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗